Bengaluru’s deep-tech startup Sophrosyne is gearing up to take its multi-vital biosensing chip from lab prototype to real-world production—fresh capital now propelling it toward production-grade silicon and early OEM rollouts.

Semiconductor startup Sophrosyne Technologies has raised USD 2 million (~INR 17.9 crore) in a seed round led by Bluehill.VC. The Bengaluru-based firm plans to accelerate product development and early customer deployments for its health-focused chip platform.

Sophrosyne is building a unified, multi‑vital biosensing system‑on‑chip (SoC) for wearables that can capture ECG, PPG, respiration, temperature and related signals while consuming very low power. The fresh capital will fund the transition from prototype silicon to production‑grade development, expand design and firmware teams, and support pilot rollouts with OEMs in India and overseas.

The startup recently cleared technical diligence under the Centre’s Design Linked Incentive (DLI) scheme and secured a grant of about USD 1.2 million (~INR 10.75 crore). The DLI programme, part of the Semicon India initiative, provides design infrastructure and incentives for domestic chip design, including reimbursements of up to 50% of eligible costs (capped at INR 15 crore) and 4%–6% incentives on sales for five years.

“We see wearable health entering a phase where accuracy and continuous monitoring become standard,” Bluehill.VC’s managing partner Sridhar Parthasarathi said, adding that innovation at the semiconductor level is crucial to hit those goals.

Dr. Manish Srivastava, co‑founder and CEO of Sophrosyne, said the funding arrives as the team moves “toward production‑grade silicon and early OEM rollouts,” noting that deep‑tech investors bring both capital and domain guidance.

Bluehill.VC, headquartered in Chennai, focuses on IP‑led deep‑tech across semiconductors, energy, advanced materials, robotics and industrial IoT; the firm is targeting an INR 350‑crore maiden fund close by end‑2025, according to earlier reports.

India’s wearable market has cooled after explosive growth, with smartwatch shipments sliding in 2024 and through H1 CY25. “Innovations will likely revolve around advanced sensing and AI, plus more sophisticated health monitoring features,” said Vikas Sharma, senior market analyst, IDC India, pointing to opportunities in precision tracking even as volumes normalise.

Highlights of Sophrosyne Seed Funding Round

• Round: $2 million seed (~INR 17.7 crore) led by Bluehill.VC; announced 21 November 2025.
• Use of proceeds: Move from prototype to production‑grade silicon; expand design/firmware teams; early OEM deployments in India and abroad.
• Product: Unified biosensing SoC for ECG, PPG, respiration, temperature; ultra‑low power for continuous monitoring.
• Grant: About USD 1.2 million under MeitY’s DLI scheme following technical diligence.
• Investor focus: Bluehill.VC targets IP‑heavy deep‑tech; aiming an INR 350‑crore maiden fund close by end‑2025.

Conclusion

Sophrosyne seed funding underscores investor appetite for foundational semiconductor IP amid a softer wearables cycle. If the company executes on production silicon and design wins with OEMs, its low‑power biosensing SoC could ride the next shift toward more accurate, always‑on health features in devices. That said, the path from lab prototypes to reliable volume production carries execution and yield risks common to chip startups.

For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription stay tuned to IPO Central.